ArticleDeutsches Arzteblatt international2012
The incidence of interval cancers in the German mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia.
Article in Deutsches Arzteblatt international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Decision aid on breast cancer screening reduces attendance rate: results of a large-scale, randomized, controlled study by the DECIDEO group.Oncotarget · 2016Trial
- Impact of Music Therapy on Neurodevelopment of Preterm Infants and Functional Improvement in Children with Neurological Deficits.Pediatric reports · 2025Review
- Risk Factors and Mortality Among Women With Interval Breast Cancer vs Screen-Detected Breast Cancer.JAMA network open · 2024Article
- German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data.BMC cancer · 2023Article
- [Systematic and quality-assured early diagnosis of sporadic breast cancer : Update on screening effects and scientific studies].Der Radiologe · 2021Review
- The Mode of Detection Is Not Associated with Quality of Life in Women with Breast Cancer.Breast care (Basel, Switzerland) · 2020Article
- Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study.BMC cancer · 2020Article
- Differences in Breast Cancer Characteristics by Mammography Screening Participation or Non-Participation.Deutsches Arzteblatt international · 2018Observational
- Article
- Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.Geburtshilfe und Frauenheilkunde · 2018Article
- Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.BMC cancer · 2018Article
- Digital mammography screening: sensitivity of the programme dependent on breast density.European radiology · 2017Article
- Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.British journal of cancer · 2017Article
- The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening.NPJ breast cancer · 2017Article
- Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009.Breast care (Basel, Switzerland) · 2016Article
- Small-area spatio-temporal analyses of participation rates in the mammography screening program in the city of Dortmund (NW Germany).BMC public health · 2015Article
- Overdiagnosis: epidemiologic concepts and estimation.Epidemiology and health · 2015Article
- [Mammography screening in Germany. Current results and future challenges].Der Radiologe · 2014Article
- Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme.PloS one · 2014Article
- Mammography Screening - as of 2013.Geburtshilfe und Frauenheilkunde · 2013Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byIn reply.2013
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer screening programs must meet high standards for quality and effectiveness, because many healthy persons need to be screened to detect relatively few cases of cancer. In this study, we use the rate of interval cancers as an important surrogate indicator for evaluating the German mammography screening program (MSP).
methodsAll first-time participants in the MSP in the German federal state of North Rhine-Westphalia over the period 2005-2008 whose screening mammogram had been read as negative were followed over the next 24 months for the potential development of breast cancer (an "interval cancer" or IC). The screening data in the MSP database were compared in anonymized fashion with reports of cancer that were recorded at the Epidemiological Cancer Registry North Rhine-Westphalia.
resultsAmong the 878,764 women with negative screening mammograms in the first screening round, 2036 (23.2 per 10,000) developed an IC in the ensuing 24 months. These ICs accounted for 40% of all T2-T4 breast cancers occurring in first-time participants in the screening program in the 2 years after screening. The relative rate of IC compared to the background incidence of breast cancer before introduction of the MSP was 27% in the first year and 58% in the second. Screening detected 78% of all breast cancers that occurred during a maximum of 2 years after screening.
conclusionThe IC rates in the implementation phase of the MSP agree with those found in other, established European programs. The present study is the first one to assess this important surrogate parameter to characterize the effectiveness of the German MSP among women in North Rhine-Westphalia, Germany's largest state by population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.